Aquestive Therapeutics Outlines Anaphylm Resubmission Timeline and 2026 Cash Runway in Investor Presentation
AQST sits 95% above its 52-week low of $2.12.
Summary
Aquestive Therapeutics provided an investor presentation outlining a detailed timeline for Anaphylm's NDA resubmission by Q3 2026, confirmed a strong cash position for 2026, and introduced a new pipeline asset, AQST-108.
Key Events · Product Development and Regulatory · AQST
-
Anaphylm NDA Resubmission Timeline
The company plans a Type A meeting with the FDA in Q1 2026 and expects to resubmit the Anaphylm New Drug Application (NDA) in Q3 2026, following the January 30, 2026 Complete Response Letter.
-
Strong Cash Position and Runway
Aquestive Therapeutics reported $121.2 million in cash and cash equivalents at the end of 2025 and anticipates finishing 2026 with significant cash, providing capital for ongoing development.
-
New Pipeline Asset Introduced
The investor presentation highlights AQST-108, an epinephrine topical gel for alopecia areata, as a new product candidate with planned clinical milestones.
Analysis · AQST · Life Sciences
This 8-K filing, accompanying an investor presentation, provides crucial updates following the recent Complete Response Letter (CRL) for Anaphylm. The company details a clear timeline for addressing FDA deficiencies, including a Type A meeting in Q1 2026 and NDA resubmission in Q3 2026. Furthermore, it reassures investors about its financial position, stating it finished 2025 with $121.2 million in cash and expects to end 2026 with significant cash, providing a runway to execute its development plans. The presentation also highlights the AQST-108 topical gel for alopecia areata as a new pipeline asset, diversifying future growth opportunities. This information is vital for investors to assess the company's path forward after the regulatory setback.
At the time of this filing, AQST was trading at $4.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $505.1M. The 52-week trading range was $2.12 to $7.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.